Bruce Ritchie

University of Alberta

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Timothy Craig

Pennsylvania State University

Henriette Farkas

Semmelweis University

William R. Lumry

Allergy Associates Research Center

Jonathan A. Bernstein

University of Cincinnati Medical Center

Emel Aygören‐Pürsün

University Hospital Frankfurt

Avner Reshef

Barzilai Medical Center

Markus Magerl

Fraunhofer Institute for Translational Medicine and Pharmacology

Konrad Bork

Johannes Gutenberg University Mainz

Bruce L. Zuraw

University of California, San Diego

Marc A. Riedl

University of California, San Diego

Cooperative Institutions

University of Alberta

119

University of Toronto

McMaster University

University of Calgary

University of Ottawa

Inserm

University of British Columbia

Monash University

Charité - Universitätsmedizin Berlin

Ottawa Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Prompt response to rituximab of severe hemolytic anemia with both cold and warm autoantibodies

American Journal of Hematology (2004)

Duncan J. Webster Bruce Ritchie Michael J. Mant

Abstract A 71‐year‐old male with severe autoimmune hemolysis with both cold agglutinins and warm antibodies was intolerant of prednisone and cyclophosphamide. Rituximab was given during a 60‐day period when he required 41 units of packed cells to maintain hemoglobin above 75 g/l. Two weeks later hemoglobin stabilized at 95 g/l, and further transfusions were not required. A second course of rituximab was given 4 months later for continued hemolysis. A satisfactory hemoglobin was maintained for 9 months from initial treatment, when hemoglobin again fell to 65 g/L. A prompt response to a third course of rituximab was obtained. This is the second patient with both cold agglutinins and warm antibodies with severe hemolytic anemia who has had a prompt response to rituximab. This treatment should be considered when a rapid response is needed or when a patient has failed to respond to more standard therapies. Am. J. Hematol. 75:258–259, 2004. © 2004 Wiley‐Liss, Inc.

Cold Agglutinin

Haptoglobin

10.1002/ajh.20034

Cite

Citations (15)

Use of Direct Oral Anticoagulants Versus Traditional Therapies for Acute Venous Thromboembolism After Direct Discharge From the Emergency Department or After Hospitalization: An Audit of 16 Canadian Hospitals

Clinical Therapeutics (2020)

Tammy J. Bungard Bruce Ritchie Jennifer Bolt Peter Thomson William Semchuk

Medical record

10.1016/j.clinthera.2020.03.001

Cite

Citations (0)

Improvement in Quality of Life Measurements in Newly Diagnosed Patients with Primary Immunodeficiency Receiving Directly Initiated Subcutaneous Replacement Therapy with Vivaglobin

Journal of Allergy and Clinical Immunology (2010)

Michael Borte Bruce Ritchie Alessandro Plebani Christine McCusker Eduardo Fernández‐Cruz

Discontinuation

10.1016/j.jaci.2009.12.550

Cite

Citations (2)

Impact of a pharmacist-managed anticoagulation clinic on clinical events

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada (2008)

Tammy J. Bungard Leslie Gardner Stephen L. Archer Peter Hamilton Bruce Ritchie

10.3821/1913-701x(2008)141[278:ioapac]2.0.co;2

Cite

Citations (2)

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update

World Allergy Organization Journal (2022)

Marcus Maurer Markus Magerl Stephen Betschel Werner Aberer Ignacio J. Ansotegui

Hereditary Angioedema

Guideline

Delphi Method

C1-inhibitor

Delphi

10.1016/j.waojou.2022.100627

Cite

Citations (115)

A Ten Year Survey of Chronic Immune Thrombocytopenic Purpura in Canadian Children, 1984–2003: Report of the Canadian Chronic ITP Working Group.

Blood (2004)

Syed Kaiser Ali Mark Belletruti Dorothy Barnard Anthony K.C. Chan Michèle David

Thrombocytopenic purpura

Hematology

10.1182/blood.v104.11.3935.3935

Cite

Citations (1)

Morphological Development of The Lung: A Review

Journal of Paediatrics and Child Health (1974)

Daine Alcorn I. G. S. Alexander J. E. Maloney Bruce Ritchie Adrian M. Walker

SYNOPSIS This literature review compares the developing lung structure of several mammalian species and identifies those features which are common at birth. Potential air‐conducting structures are formed early in gestation with the bronchial tree being developed well before the alveoli and gas exchanging structures. The distal pulmonary epithelium differentiates into alveolar type I and II cells whilst capillaries proliferate in the pulmonary mesenchyme. Late in gestation structures similar in shape to adult alveoli form and potential gas exchanging areas are detectable. Cell inclusions associated with the production of pulmonary surfactant develop during the latter part of gestation and are abundant at term. Whilst the relative rates of development of these pulmonary structures vary between species, the lung has a common fundamental architecture at birth.

Mesenchyme

10.1111/j.1440-1754.1974.tb02919.x

Cite

Citations (9)

Can Subcutaneous IgG Therapy Provide Rapid and Sufficient Serum IgG Levels in Initiation and High Dose Maintenance Settings?

Journal of Allergy and Clinical Immunology (2010)

Jordan S. Orange Mark R. Stein Hilary Longhurst Michael Borte Bruce Ritchie

Multifocal motor neuropathy

Tolerability

Maintenance therapy

Maintenance dose

10.1016/j.jaci.2009.12.545

Cite

Citations (0)

Studies of lobar function in the lungs of patients with emphysema.

PubMed (1966)

Bruce Ritchie P. Hugh‐Jones

Pulmonary emphysema

Source

Cite

Citations (2)

[WAO Guideline for the Management of Hereditary Angioedema].

PubMed (2015)

Timothy Craig Emel Aygören Pürsün Konrad Bork Tom Bowen Henrik Boysen

Hereditary Angioedema (HAE) is a rare disease and for this reason proper diagnosis and appropriate therapy are often unknown or not available for physicians and other health care providers. For this reason we convened a group of specialists that focus upon HAE from around the world to develop not only a con- sensus on diagnosis and management of HAE, but to also provide evidence based grades, strength of evidence and classification for the consensus. Since both consensus and evidence grading were adhered to the document meets criteria as a guideline. The outcome of the guideline is to improve diagnosis and management of patients with HAE throughout the world and to help initiate uniform care and availability of therapies to all with the diagnosis no matter where the residence of the individual with HAE exists.

Hereditary Angioedema

Guideline

Grading (engineering)

10.15036/arerugi.64.1215

Cite

Citations (30)